Compare Quest Diagnostics Inc (DGX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Wipro Limited — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Wipro Limited trades at $1.86 (market cap $18.57B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Wipro Limited pays the higher dividend (10.42%). Which is the better fit depends on your goals.
| DGX | WIT | |
|---|---|---|
Market Cap | $22.80B | $18.57B |
Sector | Health | Technology |
52-Week High | $216.02 | $3.06 |
52-Week Low | $166.42 | $1.82 |
Enterprise Value | $28.82B | $14.96B |
Dividend Yield | 1.67% | 10.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
WIT trades at $1.90, up 1.6% with bearish technical signals despite recent AI partnership announcements. The company shows mixed fundamentals with declining revenue from $904.9B in 2023 to $890.9B in 2025, though net income improved to $131.4B with a 14.74% margin. Recent earnings misses and weak guidance have tempered investor enthusiasm despite strong cash flow generation and AI initiatives.
WIT presents a cautious outlook with analyst consensus leaning bearish (19% buy vs 33% sell). While valuation appears reasonable (P/E 14.27) and AI partnerships offer growth potential, persistent revenue declines and execution risks in a competitive IT services market warrant careful monitoring. The stock faces near-term pressure from technical weakness and growth concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
